RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC

NCT05220748 | Withdrawn Phase 1 FDA Drug FDA Device

• 1 other identifier: RM-1995-101
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

A phase 1a/1b, open-label, RM-1995 drug-dose escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of RM-1995 photoimmunotherapy treatment as monotherapy (phase 1a) or combined with pembrolizumab (phase 1b) in patients with cutaneous squamous cell carcinoma (cuSCC) or head and neck squamous cell carcinoma (HNSCC) that has progressed despite all available standard therapies.

Conditions

Cutaneous Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma

Keywords

Rakuten Medical; RM-1995; RM-1995-101; HNSCC; CUSCC; head and neck squamous cell carcinoma; cutaneous squamous cell carcinoma; PIT; photoimmunotherapy; skin cancer; skin; head and neck cancer

Outcome Measures

Primary Outcomes (2)

• Phase 1a Monotherapy: Evaluate the safety and tolerability of RM-1995 PIT treatment, and determine the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD).

  Incidence of dose-limiting toxicities (DLTs), frequency of adverse events, and MTD or MAD

  24 months

• Phase 1b Combination Therapy: Evaluate the safety and tolerability of RM-1995 PIT treatment in combination with pembrolizumab and determine the MTD or MAD.

  Incidence of dose-limiting toxicities (DLTs), frequency of adverse events, and MTD or MAD

  24 months

Secondary Outcomes (4)

• Serum concentration of RM-1995.

  Various timepoints from Cycles 1, 2, and 3, Day 1 through Day 21. Each cycle is 21 days.

• Serum concentration of total antibody.

  Various timepoints from Cycles 1, 2, and 3, Day 1 through Day 21. Each cycle is 21 days.

• Serum concentration of IR-700.

  Various timepoints from Cycles 1, 2, and 3, Day 1 through Day 21. Each cycle is 21 days.

• Assess antitumor activity of RM-1995.

  24 months

Study Arms (2)

RM-1995 Photoimmunotherapy (Phase 1a Monotherapy)

EXPERIMENTAL

Patients with locally advanced cuSCC or HNSCC or metastatic disease that has recurred or progressed, despite all available standard therapies.

Combination Product: RM-1995

RM-1995 Photoimmunotherapy + Pembrolizumab (Phased 1b Combination Therapy)

EXPERIMENTAL

Patients with locally advanced cuSCC or HNSCC or metastatic disease that has recurred or progressed, despite all available standard therapies.

Combination Product: RM-1995; Biological: Pembrolizumab

Interventions

RM-1995 COMBINATION_PRODUCT

RM-1995 will be administered by intravenous (IV) infusion followed approximately 24 hours later by tumor illumination with 690 nm non thermal red light using the PIT690 Laser System. The starting dose of RM-1995 will be 0.25 mg/kg and escalated up to 2.0 mg/kg over 6 dosing cohorts

RM-1995 Photoimmunotherapy (Phase 1a Monotherapy); RM-1995 Photoimmunotherapy + Pembrolizumab (Phased 1b Combination Therapy)

Pembrolizumab BIOLOGICAL

Pembrolizumab (200 mg) will be administered by intravenous (IV) infusion one week before the first RM-1995 PIT treatment and the second dose three weeks later for patients in the combination arm. Once the DLT window is complete, pembrolizumab dosage will be maintained at either 200 mg Q3w, or shift to 400 mg Q6w, per investigator discretion.

RM-1995 Photoimmunotherapy + Pembrolizumab (Phased 1b Combination Therapy)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient must be at least 18 years old.
• Patient must have tumor types of head and neck squamous cell carcinoma (HNSCC), cutaneous squamous cell carcinoma (cuSCC)
• Locally advanced or locoregional disease that has recurred or progressed on or after at least one prior line of therapy, which must include prior platinum-based chemotherapy, and is not eligible for further locoregional treatment (ie, standard surgery or radiation), or for which locoregional treatment has proved to be intolerable or is medically contraindicated.
• Metastatic disease that has recurred or progressed following prior platinum-based chemotherapy, prior immunotherapy with PD-(L)1 inhibitors, or other standard of care systemic treatment, has proven to be ineffective, intolerable, or is considered medically contraindicated in the opinion of the Investigator
• Patient must have tumors with at least one superficial lesion of the skin or oral cavity, not deeper than 1 cm and that is accessible for photoimmunotherapy treatment. Note: Lesions that are in the pharynx and larynx will not be included in the treatment.
• Patient must have the ability to provide representative tumor specimens with an associated pathology report.
• Patient must have measurable disease by RECIST 1.1 as assessed by Investigator.
• Patient must have ECOG performance status of 0 to 2 at the time of screening
• Patient has life expectancy ≥ 3 months based on Investigator's judgement.
• Adequate organ function laboratory values (Hematology, Hepatic, Renal and Coagulation).
• Female patients of childbearing potential must not be pregnant or breastfeeding and must be willing to use 2 methods of highly effective birth control, or practice abstinence throughout the study and for at least 120 days after the last dose of study medication.
• Male patients must be sterile or agree to use an adequate method of contraception or practice abstinence starting with the first dose of study medication and for at least 120 days after the last dose of study medication.

You may not qualify if:

• Receiving any other investigational agents, approved anticancer therapies, including chemotherapy, hormonal therapy, ultraviolet-light therapy, or other topical therapy within 2 weeks or 5 half-lives, whichever is longer, before initiation of study treatment, with the following exceptions:
• Hormone-replacement therapy or oral contraceptives
• Herbal therapy, including herbal therapy intended as anticancer therapy and medicinal cannabinoids taken to reduce symptom burden, must be discontinued at least 1 week before the first dose of pembrolizumab (combination therapy) or the first dose of RM-1995 (monotherapy)
• Palliative radiotherapy for painful boney metastases or metastases in potentially sensitive locations (eg, epidural space) must be completed \> 2 weeks before the first dose of pembrolizumab (combination therapy) or the first dose of RM 1995 (monotherapy)
• Previously initiated bisphosphonate or denosumab therapy for bone metastases may be continued during study participation.
• Treated with local radiation therapy within 12 weeks before the first dose of study treatment. Patients must have recovered from all radiation-related toxicities to Grade \< 1 or baseline and must not require steroids.
• Treatment with systemic immunostimulatory agents not described above (including but not limited to IFN-α, IL-2) within 6 weeks or 5 half-lives of the drug, whichever is shorter, before the first dose of study treatment.
• Adverse events from prior anticancer therapy that have not resolved to Grade ≤ 1, except for alopecia or endocrinopathy managed with replacement therapy.
• Patients who have tumors at sites that may compromise sensitive and vital anatomic structures.
• Malignancies other than disease under study within 3 years prior to treatment start, except for those with a negligible risk of metastasis or death.
• Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within the previous 3 months, unstable arrhythmias, or unstable angina.
• Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis, cirrhosis, or inherited liver disease.
• Prior allogeneic bone marrow transplantation or prior solid organ transplantation.
• Known history of testing positive for human immunodeficiency virus or acquired immunodeficiency syndrome -related illness.
• Known infection or detection of active Hepatitis B (e.g., HBsAg positive), Hepatitis C (eg, RNA \[qualitative\]), or SARS-CoV-2 (qualitative).

Sponsors & Collaborators

• Rakuten Medical, Inc.: lead

MeSH Terms

Conditions

Squamous Cell Carcinoma of Head and Neck; Skin Neoplasms; Head and Neck Neoplasms

Interventions

pembrolizumab

Condition Hierarchy (Ancestors)

Carcinoma, Squamous Cell; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Naomi Schechter

  Rakuten Medical, Inc.

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 11, 2022
• First Posted: February 2, 2022
• Study Start: March 24, 2022
• Primary Completion: January 30, 2023
• Study Completion: January 30, 2023
• Last Updated: April 19, 2023

Record last verified: 2023-04

Data Sharing

• IPD Sharing: Will not share